Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial

Fig. 1

Treatment protocol for eligible patients. Patients randomly assigned to the MSC group received MSCs plus basiliximab, and the control group received basiliximab alone. MSCs were administered once a week for 4 weeks as a cycle. Further administrations of MSCs were given if the patients achieved PR at week 4. Basiliximab was administered twice in the first week and once a week until aGVHD was reduced to grade < II. MSCs, mesenchymal stromal cells; CR, complete response; PR, partial response; NR, no response

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us